Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 237 across all filing types
Latest filing 2026-06-13 Investor Presentation
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is an official notification from Concord Biotech Limited to stock exchanges regarding scheduled meetings with analysts and institutional investors. It explicitly states the nature, date, and mode of the meetings, and confirms that no unpublished price sensitive information will be discussed. The document cites compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) regulations and is submitted pursuant to Regulation 30(6) related to disclosures of events or information. The text is short (2005 characters) and serves as a formal advisory rather than a report or detailed presentation. This corresponds to an Investor Presentation announcement or update on engagements with investors rather than the presentation itself. Therefore, it should be classified as Investor Presentation (IP) rather than earnings release or a full report. The document is clearly positioned as an announcement of meetings with investors and analysts under SEBI regulations, fitting best into the Investor Presentation category.
2026-06-13 English
Intimation of Schedule of Analyst / Institutional Investor meeting to be held on June 17, 2026 at 10:30 AM
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about scheduled meetings between company officials and analysts/investors. It emphasizes compliance with SEBI listing regulations and states that no unpublished price sensitive information will be shared. There are no financial statements, results, or discussions of performance or governance. The text is around 2000 characters, indicating it is a brief announcement rather than a full report. This fits the description of Regulatory Filings (RNS), as it is a regulatory compliance announcement that does not fit into other specific categories such as earnings releases, presentations, or shareholder votes.
2026-06-13 English
Updates
Regulatory Filings Classification · 85% confidence The document is a formal announcement to stock exchanges notifying the completion of an ANVISA inspection at the company’s manufacturing facility. It contains no financial statements, no vote results, no management changes, and no detailed report; it is a compliance/regulatory update. This fits the catch-all “Regulatory Filings” category rather than a specific report type.
2026-06-12 English
We are pleased to announce the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection ....
Regulatory Filings Classification · 85% confidence The document is a compliance announcement addressed to stock exchanges (NSE and BSE) informing them of the successful completion of an ANVISA inspection at the company’s manufacturing facility. It does not contain financial results, board changes, share transactions, or AGM materials. It is a general regulatory announcement and falls under the fallback category for miscellaneous regulatory communications.
2026-06-12 English
General Updates
Regulatory Filings Classification · 75% confidence The document is an immediate stock exchange disclosure under SEBI Regulation 30 announcing USFDA approval of a new drug ANDA. It is not a financial report, management discussion, earnings release, or AGM material – it is a regulatory/compliance announcement of a material event. It falls into the miscellaneous regulatory announcement category.
2026-06-10 English
We are pleased to inform that the Company has received approval from USFDA for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg.
Regulatory Filings Classification · 92% confidence The document is a stock exchange filing under SEBI LODR Regulation 30 announcing receipt of USFDA approval for an ANDA product. It contains no financial statements, results, or detailed investor presentation—it is a compliance/regulatory announcement. Therefore, it falls under General Regulatory Filings (RNS).
2026-06-10 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.